Repository logo
 

Digital endpoints in clinical trials: emerging themes from a multi-stakeholder Knowledge Exchange event

Published version
Peer-reviewed

Repository DOI


Change log

Abstract

Abstract Background Digital technologies, such as wearable devices and smartphone applications (apps), can enable the decentralisation of clinical trials by measuring endpoints in people’s chosen locations rather than in traditional clinical settings. Digital endpoints can allow high-frequency and sensitive measurements of health outcomes compared to visit-based endpoints which provide an episodic snapshot of a person’s health. However, there are underexplored challenges in this emerging space that require interdisciplinary and cross-sector collaboration. A multi-stakeholder Knowledge Exchange event was organised to facilitate conversations across silos within this research ecosystem.

            Methods
            A survey was sent to an initial list of stakeholders to identify potential discussion topics. Additional stakeholders were identified through iterative discussions on perspectives that needed representation. Co-design meetings with attendees were held to discuss the scope, format and ethos of the event. The event itself featured a cross-disciplinary selection of talks, a panel discussion, small-group discussions facilitated via a rolling seating plan and audience participation via Slido. A transcript was generated from the day, which, together with the output from Slido, provided a record of the day’s discussions. Finally, meetings were held following the event to identify the key challenges for digital endpoints which emerged and reflections and recommendations for dissemination.
          
            Results
            Several challenges for digital endpoints were identified in the following areas: patient adherence and acceptability; algorithms and software for devices; design, analysis and conduct of clinical trials with digital endpoints; the environmental impact of digital endpoints; and the need for ongoing ethical support. Learnings taken for next generation events include the need to include additional stakeholder perspectives, such as those of funders and regulators, and the need for additional resources and facilitation to allow patient and public contributors to engage meaningfully during the event.
          
            Conclusions
            The event emphasised the importance of consortium building and highlighted the critical role that collaborative, multi-disciplinary, and cross-sector efforts play in driving innovation in research design and strategic partnership building moving forward. This necessitates enhanced recognition by funders to support multi-stakeholder projects with patient involvement, standardised terminology, and the utilisation of open-source software.

Description

Acknowledgements: The authors would like to thank Cecilia Mascolo, Anne Blackwood, Evelyne Priestman and the patient and public contributors for their participation and contributions in the Knowledge Exchange event. The authors would like to thank Alison Quenault, the communications and events manager at the MRC-Biostatistics Unit, for her help with organising and running the event. Finally, the authors give special thanks to patient and public contributors Yazan Mehyar and Lorraine Hazlehurst for their contributions towards this paper.


Funder: All Council Harmonised IAA Rapid Response Award


Funder: Cambridge Centre for Data-Driven Discovery


Funder: IDEA-FAST


Funder: Alzheimer's Society

Journal Title

Trials

Conference Name

Journal ISSN

1745-6215

Volume Title

25

Publisher

Springer Science and Business Media LLC

Rights and licensing

Except where otherwised noted, this item's license is described as Attribution 4.0 International
Sponsorship
NIHR Cambridge Biomedical Research Centre (NIHR203312)
Medical Research Council (MC UU 00002/15, MC UU 00002/15, MC UU 00040/03, MC UU 00004/07, MC UU 00040/03)
Horizon 2020 Framework Programme (101016775)
HORIZON EUROPE Framework Programme (821511)
Innovative Medicines Initiative 2 Joint Undertaking (806999)
MRC Experimental Medicine Award (MR/W026279/1)